Related Experiment Videos
Chromosome 16 abnormalities associated with myeloid malignancies
L J Campbell1, J Challis, T Fok
1Department of Cytogenetics, St. Vincent's Hospital, Melbourne, Australia, Victoria.
Genes, Chromosomes & Cancer
|January 1, 1991
Summary
Chromosome 16 abnormalities in myeloid leukemia patients indicate a good prognosis, regardless of specific subtype or additional genetic changes. This finding holds true even with morphological variations, suggesting a consistent survival benefit.
Area of Science:
- Hematology
- Cytogenetics
- Oncology
Background:
- Myeloid malignancies encompass a range of blood cancers.
- Cytogenetic abnormalities, particularly involving chromosome 16, are recognized in certain myeloid leukemias.
- The prognostic significance of chromosome 16 alterations across various myeloid leukemia subtypes requires further elucidation.
Purpose of the Study:
- To investigate the clinical and prognostic implications of chromosome 16 abnormalities in myeloid leukemia.
- To determine if morphological variations or additional cytogenetic aberrations influence outcomes in patients with chromosome 16 alterations.
- To assess the impact of chromosome 16 abnormalities on treatment response, survival rates, and central nervous system relapse.
Main Methods:
- Retrospective analysis of 26 myeloid leukemia patients with chromosome 16 abnormalities (inversion 16 or t(16;16)) over a 6-year period.
- Review of cytogenetic data, morphological classifications (including M4Eo), eosinophil status, and additional chromosomal abnormalities.
- Evaluation of treatment outcomes, including complete remission rates, survival data (median survival, 2- and 5-year survival), and CNS relapse incidence.
Main Results:
- Eighty-five percent (22/26) of patients exhibited abnormal eosinophils.
- Despite morphological variations (M4Eo, M2, M4, M5, RAEB, RAEB-T), patients with chromosome 16 abnormalities showed high complete remission rates (87%) and favorable survival (median 188 weeks).
- Additional cytogenetic abnormalities did not significantly impact prognosis, and CNS relapse was infrequent (8%).
Conclusions:
- Chromosome abnormalities involving 16p13 and 16q22 define a good-prognosis subset of myeloid leukemia.
- The improved prognosis associated with chromosome 16 alterations appears independent of specific morphological subtypes or additional cytogenetic findings.
- These findings support the routine cytogenetic analysis for identifying patients who may benefit from targeted treatment strategies and improved prognostic assessment.